Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis.
Immunopathogenesis of neuromyelitis optica.
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.
Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System.
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
HLA-DRB1*15:01 and multiple sclerosis: a female association?
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies.
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS
Sex ratio of multiple sclerosis and clinical phenotype.
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
T(H)17 cytokines in autoimmune neuro-inflammation.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Testosterone treatment in multiple sclerosis: a pilot study.
The relevance of animal models in multiple sclerosis research.
The natural history of primary progressive MS in British Columbia, Canada.
Best practice in the use of natalizumab in multiple sclerosis.
MHC transmission: insights into gender bias in MS susceptibility.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Integrating Acupuncture Within a Wellness Intervention for Women With Multiple Sclerosis: A Feasibility Study.
Biogen Idec reports positive top-line results from Phase 2 anti-LINGO-1 trial in people with acute optic neuritis
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

Pages